Podcasts about ivc

With Kevin Damman, University Medical Center Groningen, Groningen - The Netherlands, Floran Sahiti, University Hospital of Wurzburg, Wurzburg - Germany, Joao Pedro Ferreira, University of Porto, Porto - Portugal, Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia, Marat Fudim, Duke University Medical Center, Durham, NC - USA, Gregorio Tersalvi, Mayo Clinic, Rochester, MN - USA, Jose Luis Morales Rull, University Hospital Arnau de Vilanova, Lleida - Spain and Cornelia Margineanu, Bucharest - Romania. In this episode, we discuss four late-breaking clinical trials presented at the Heart Failure Congress 2025 in Belgrade, Serbia. First, Kevin Damman presents the results of FUTURE-HF, a first-in-human study evaluating the long-term safety, accuracy, and clinical utility of a novel implantable IVC sensor for remote heart failure management. Next, Joao Pedro Ferreira highlights the key findings of SOGALDI-PEF, a crossover trial comparing SGLT2 inhibitor monotherapy versus combination therapy with an SGLT2 inhibitor and a mineralocorticoid receptor antagonist (MRA) in reducing NT-proBNP levels. Third, Marat Fudim reports on the MUSIC-HFpEF phase 1/2a trial, which explores the safety and preliminary efficacy of a novel gene therapy using adeno-associated virus vectors in patients with HFpEF. Finally, Jose Luis Morales Rull shares insights from PREFER-HF, a study assessing the effects of intravenous or oral iron therapy versus placebo in patients with HFpEF and iron deficiency anemia. FUTURE-HF: Long-term safety, accuracy, and utility of a novel implantable IVC sensor for remote HF management - Kevin Damman, University Medical Center Groningen, Groningen, The Netherlands. Host: Floran Sahiti, University Hospital of Wurzburg, Wurzburg, Germany doi: 10.1016/j.jchf.2025.01.019. SOGALDI-PEF: SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with preserved ejection fraction – Joao Pedro Ferreira, University of Porto, Porto, Portugal. Host: Novi Yanti Sari, Siloam Hospitals Group, Jakarta (Indonesia).  MUSIC-HFpEF: Gene therapy in Heart Failure with Preserved Ejection Fraction – Marat Fudim, Duke University Medical Center, Durham, NC, USA. Host: Gregorio Tersalvi, Mayo Clinic, Rochester, MN, USA PREFER¬-HF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia - Jose Luis Morales Rull, University Hospital Arnau de Vilanova, Lleida, Spain. Host: Cornelia Margineanu, Bucharest, Romania. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

In this conversation, Dr. Peter Weimersheimer discusses various techniques and tips for performing cardiac ultrasound in emergency medicine. He emphasizes the importance of understanding probe movements such as sliding, fanning, and rocking to optimize cardiac views. The discussion also covers troubleshooting common challenges in cardiac imaging, the critical role of gel in obtaining clear images, and the transition between different cardiac views. Dr. Weimersheimer emphasizes the importance of identifying cardiac pathologies through ultrasound and shares techniques for obtaining the apical four-chamber view. The conversation concludes with insights into the impact of ultrasound on patient care and decision-making in emergency situations. In this conversation, Dr. Peter Weimersheimer shares his expertise on cardiac ultrasound techniques, with a focus on the apical four-chamber view and the importance of understanding ventricular shape and function. He discusses practical tips for navigating ultrasound views in critical situations, optimizing imaging techniques, and utilizing patient physiology to enhance imaging quality. The conversation also covers the interpretation of right ventricular size in cardiac arrest and differentiating between the inferior vena cava (IVC) and aorta during ultrasound imaging.

Dies hier ist nicht LEBEN: In dieser Aleph-Session zum Monats-Thema, mit dieser neuen Serie "Alle Wunder bedeuten Leben und GOTT ist der Geber des Lebens", teilen wir, was es mit dieser Idee auf sich hat, welche Aspekte wir grundsätzlich in unserem Geist als Angebot zur wundergesinnten Erkenntnis vorfinden. Wir gehen darauf ein, was die "Leben" im wahren Sinne als LEBEN erkannt und angenommen wird. Jesus geht im Kurs höchst kompromisslos mit diesem Begriff um, und lehrt unaufhörlich, dass LEBEN kein Gegenteil hat, noch haben kann, und fordert uns auf, alle Investition in die Idee des Todes aufzugeben. Wir wenden uns Seinem Angebot zu, das uns ein ewiges HIER-Präsent-SEIN finden und anerkennen eröffnet. ◊ Devavan teilt mit dir Textstellen aus Ein Kurs in Wundern, der Lektion 71-5., und aus Kap. 12-IV-7./6., 29-II-6.-7. und 19-IV-C-1.-2., sowie aus dem veröffentlichten Buch von Devavan “3 Tage zum Erwachen”, Tag 2 aus "I. Sich GOTT hingeben", S. 48-50 ◊ ◊ Ein Kurs in Wundern Session mit Devavan am 12.03.2025, veranstaltet von der Aleph Akademie. Weitere Termine und Infos unter www.aleph-akademie.de In Freude zusammen nach Hause gehen mit und durch die Lehren von Ein Kurs in Wundern. YouTube: https://youtu.be/f-nOUd9BFpg

Entrevista en "A TIEMPO" (IVC): MWC 2025 desde BarcelonaLa reciente entrevista en el programa "A TIEMPO" de IVC, conducida por Eduardo Rodríguez y Saúl Noriega, ofreció una visión profunda y esclarecedora sobre los aspectos más destacados del Mobile World Congress (MWC) 2025, directamente desde el corazón del evento en Barcelona, España.Puntos Clave de la Entrevista:Cobertura Exhaustiva:Análisis del Impacto Económico:Enfoque en la Innovación:Perspectiva Global:Claridad y Accesibilidad:

In this episode, we have a large news slate: Netflix goes all in on 'Squid Game', Low-cost airlines lift small cities, and IVC partner turnover pace quickens. Roundtable: a Look back at 2024 and what's to come in 2025: https://www.instagram.com/delano.saporu/?hl=en. Connect with me here also: https://newstreetadvisorsgroup.com/social/. Want to support the show? Feel free to do so here! https://anchor.fm/delano-saporu4/support. Thank you for listening. --- Support this podcast: https://podcasters.spotify.com/pod/show/delano-saporu4/support

Contributor: Aaron Lessen MD Educational Pearls: Pregnant patients at high risk of cardiac arrest, in cardiac arrest, or in extremis require special care A useful mnemonic to recall the appropriate management of critically ill pregnant patients is TOLDD T: Tilt the patient to the left lateral decubitus position This position relieves pressure exerted from the uterus onto the inferior vena cava, which reduces cardiac preload If the patient is receiving CPR, an assistant should displace the uterus manually from the IVC towards the patient's left side O: Administer high-flow adjunctive oxygen  L: Lines should be placed above the diaphragm Lines below the diaphragm are ineffective due to uterine compression of the IVC May consider humeral interosseous line vs. internal jugular or subclavian central line D: Dates should be estimated > 20 weeks, can consider a resuscitative hysterotomy (previously known as perimortem c-section) to improve chances of survival The uterus is palpable at the umbilicus at 20 weeks and 1 cm superior to the umbilicus for every week thereafter D: Call the labor and delivery unit for additional help References ACOG Practice Bulletin No. 211 Summary: Critical Care in Pregnancy. Obstetrics & Gynecology. 2019;133(5) Fujita N, Higuchi H, Sakuma S, Takagi S, Latif MAHM, Ozaki M. Effect of Right-Lateral Versus Left-Lateral Tilt Position on Compression of the Inferior Vena Cava in Pregnant Women Determined by Magnetic Resonance Imaging. Anesth Analg. 2019;128(6):1217-1222. doi:10.1213/ANE.0000000000004166 Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac Arrest in Pregnancy. Circulation. 2015;132(18):1747-1773. doi:doi:10.1161/CIR.0000000000000300 Singh, Ajay; Dhir, Ankita; Jain, Kajal; Trikha, Anjan1. Role of High Flow Nasal Cannula (HFNC) for Pre-Oxygenation Among Pregnant Patients: Current Evidence and Review of Literature. Journal of Obstetric Anaesthesia and Critical Care 12(2):p 99-104, Jul–Dec 2022. | DOI: 10.4103/JOACC.JOACC_18_22  Summarized & Edited by Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

Pulmonary emboli in Trauma patients is, unfortunately, an established and not uncommon complication we must deal with. Today, we welcome one of our own Trauma Surgeons, Dr Brent Emigh, MD to the Podcast to discuss VTE occurance and prophylaxis in Trauma patients. Article with more information on PE in Trauma patients is HERE Article mentioned on IVC filters can be accessed HERE If anyone has comments on this episode or suggestions for topics please feel free to reach out to me at kenneth_lynch@brown.edu

As a slightly different approach to this episode, John Redbonds heads to BVNA Congress to hear nurse's thoughts on the current lay of the land, and invites a few special guests to share their thoughts as well.   (00:00) John introduces the podcast and his co host – eLearning.vets head of education, Amelia Sherwood, looking into Veterinary Nursing in Dermatology, with conversations with Veterinary Nurses and industry people. Starting with some conversations from the British Veterinary Nursing Association Congress.   Chapter 1: VN Dermatology at BVNA congress – the challenges and the opportunities.   (02:12) John has a conversation with a couple of nurses working for a small group of practices that are involved in dermatology, without specialising. They reflect on some of the ways they have found to work more on dermatology, along with some of the challenges.   (05:49) John then speaks to two nurses working in a charity based PDSA practice, where they do the majority of dermatology work, and the cases are worked up thoroughly and fully – they reflect on why this is the case and why nurses do this more and how this shows that this is the most sensible and correct model.   (08:26) John speaks to Paris, a nurse who is interested and trained in dermatology – and sees the cases, but is unable to put her skills to use because the practice she is working at doesn't utilise those skills.   (10:25) John speaks to someone working for a company called VN Recruitment – to discuss options which exist for nurses with an interest in dermatology to find a practice where they can use their skills.   Chapter 2: VN Dermatology Nursing in a corporate industry.   (12:45) John then speaks to representatives for the corporate groups to see if there were opportunities are present for nurses in CVS, VetPartners and IVC to progress in dermatology – and specialist centres and training programmes to exist, if a nurse pursues that route.   (17:50) John has a conversation with a nurse who had been heavily involved in dermatology work, but been made redundant by the group she worked for – with no options as a result locally to work as a vet nurse due to competition for places. Demonstrating the challenges that exist in the current landscape.   Chapter 3: VN Dermatology on the move.   (20:55) John spoke to Claire, a nurse who uses a more district nursing model to deliver her nursing skill set – showing there are ways for nurses to diversify within this landscape – and whilst she has some involvement in dermatology in partnership with her local practice, she recognised there could be more opportunity and potential for this.   (27:00) John speaks to Nicola Swales, the dermatology nurse at paragon referrals, who moved 4 hours across country to work as a dermatology nurse having worked at Langford referrals previously. Nicola shares how heavily she is involved in this process, showing just how involved nurses can be.   (34:12) John wraps the podcast by speaking to Amelia Sherwood, a veterinary nurse who has worked in wound management and the advancement in the nurse role in a large group; she shares her thoughts on where the veterinary nurse industry is currently and reflects on the challenges and opportunities there are for nurses.

ABOUT THIS EPISODEIn this 2-part series, Dr. Osman Ahmed from the University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques, including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures.TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY PART 2:1. What do patients need to know about bland embolization (TAE)? a. What are the possible side effects? b. How do the size of beads play a role? c. When is this recommended? d. Do you always do both sides of the liver? If so, what is the timing and why? e. What is the recovery like? What is post-embolization syndrome?2. What do patients need to know about chemoembolization (TACE)?a. What drug is used & does this go through the whole body? b. What is the recovery like? What are the possible side effects?3. What do patients need to know about radioembolization (TARE, SIRT, y90)? a. In the era of PRRT, is there a concern with using y90 or radioembolization? How is the approach and technique used with radioembolization different than how it was done in the past? Is there a total lifetime limit of radiation?b. What is the recovery like? What are the possible side effects?4. Is there a limit to how much LDT one can do? Can they be repeated?5. How does one decide between the various types of liver-directed therapies?6. Is there a sequencing to treatments?7. Are there certain treatments that make you ineligible for other treatments? [PRRT, chemo, y90 etc] 8. If someone has had surgery such as a Whipple or surgery or procedures involving the bile duct, such as a stent in the bile duct or surgical removal of part of the bile duct, how does this weigh into the decision-making process for LDT?9. How do you determine if the treatment “worked?” What is the follow-up like? What scan might you do and in what timing?10. What do you see as the future of liver-directed therapy in neuroendocrine cancer treatment? MEET DR. OSMAN AHMEDOsman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.For more information, visit https://www.lacnets.org/lacnets-podcastFor more information, visit LACNETS.org.

This week's topics include very early medication abortion, predicting who needs a defibrillator after MI, removal of IVC filters, and early sugar exposure, hypertension and diabetes.

ABOUT THIS EPISODEIn this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are.TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY:What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?”What are the types of liver-directed therapies used for neuroendocrine cancer? Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective?When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy?What is the ablation zone? What is a heat sink effect?What is histotripsy? How does it work?When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver?What are the limitations to histotripsy? What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET? How do you decide between the various types of liver-directed therapies? MEET DR. OSMAN AHMED:Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.Visit lacnets.org/podcast/38 for the podcast, transcript, and resources. For more information, visit LACNETS.org.

Summary This week Anna (https://x.com/AnnaRRose) catches up with Zac Williamson (https://x.com/Zac_Aztec) & Ariel Gabizon (https://x.com/rel_zeta_tech) from Aztec (https://aztec.network/). They explore what's new since they were both on the show last spring before diving into the pair's work over the last year, covering everything from Zac's contributions to Aztec 3 to Ariel's latest research on IVC with his publications of the Protostar and Stackproofs works. Here's some additional links for this episode: [Episode 273: History of Plonk, Noir, and the building of Aztec 3(]https://zeroknowledge.fm/273-2/) Episode 274: SNARKs: A Trilogy with Ariel Gabizon (https://zeroknowledge.fm/274-2/) 5:51 * zkSummit: plookup: Speeding up the PLONK prover - Zac Williamson & Ariel Gabizon (https://www.youtube.com/watch?v=Vdlc1CmRYRY) 13:01 * HyperNova: Recursive arguments for customizable constraint systems by Kothapalli and Setty (https://eprint.iacr.org/2023/573.pdf) 13:01 * ProtoStar: Generic Efficient Accumulation/Folding for Special Sound Protocols by Bünz and Chen (https://eprint.iacr.org/2023/620.pdf) 27:24 * cq: Cached quotients for fast lookups by Eagen, Fiore and Gabizon (https://eprint.iacr.org/2022/1763.pdf) 34:54 * Delegating Computation: Interactive Proofs for Muggles by Goldwasser, Kalai and Rothblum (https://www.microsoft.com/en-us/research/wp-content/uploads/2016/12/2008-DelegatingComputation.pdf) 34:54 * Unlocking the lookup singularity with Lasso by Setty, Thaler and Wahby (https://people.cs.georgetown.edu/jthaler/Lasso-paper.pdf) 36:36 * Stackproofs: Private proofs of stack and contract execution using Protogalaxy by Eagen, Gabizon, Sefranek, Towa and Williamson (https://eprint.iacr.org/2024/1281.pdf) 54:32 * Accumulation without Homomorphism by Bünz, Mishra, Nguyen and Wang (https://eprint.iacr.org/2024/474.pdf) 55:24 * Aztec.network (https://aztec.network/) Check out the ZK Jobs Board (https://jobsboard.zeroknowledge.fm/) for the latest jobs in ZK at jobsboard.zeroknowledge.fm (https://jobsboard.zeroknowledge.fm/) zkSummit12 is happening in Lisbon next week on Oct 8th! Applications to attend are now open at zksummit.com (https://www.zksummit.com/), apply today as early bird tickets are limited! Episode Sponsors Attention, all projects in need of server-side proving, kick start your rollup with Gevulot's ZkCloud, the first zk-optimized decentralized cloud! Get started with a free trial plus extended grant opportunities for premier customers until Q1 2025. Register at Gevulot.com (https://gevulot.com/). Aleo (http://aleo.org/) is a new Layer-1 blockchain that achieves the programmability of Ethereum, the privacy of Zcash, and the scalability of a rollup. As Aleo is gearing up for their mainnet launch in Q1, this is an invitation to be part of a transformational ZK journey. Dive deeper and discover more about Aleo at http://aleo.org/ (http://aleo.org/). If you like what we do: * Find all our links here! @ZeroKnowledge | Linktree (https://linktr.ee/zeroknowledge) * Subscribe to our podcast newsletter (https://zeroknowledge.substack.com) * Follow us on Twitter @zeroknowledgefm (https://twitter.com/zeroknowledgefm) * Join us on Telegram (https://zeroknowledge.fm/telegram) * Catch us on YouTube (www.youtube.com/channel/UCYWsYz5cKw4wZ9Mpe4kuM_g)

Podcastはこちら: https://youtu.be/L2dBqCeCilI 「Web3 Arcade」 by IVC & YGG Japan: https://lu.ma/97cgsrb3 TON開発者ミートアップ：ミニアプリやゲーム https://lu.ma/pkyq4udc 【沖縄開催】NOT A HOTEL DAO説明会 ~NOT A HOTELのビジネスモデルとWeb3戦略~ https://1006-okinawa.peatix.com/ アジェンダ: 1.web3を初心者に説明してみる 2.実社会をよくしているの？分散性とか誰からも必要とされていないのでは？ 3.関係者はお金のことしか考えていないよね 4.どうして社会にweb3が必要なの？ 5.今のweb3現実ってどうなの？地に足ついていないのでは？ 6.UXの悪さ、ガバナンスの未熟さ、短期視点のプロジェクト、memeのノリ、既存システムの統合の難しさ インターネットは個人をエンパワーするもの/私有私財権が法規制された後の人口増加率/資本主義によって世界は裕福になっている/AI時代がweb3の必然性を加速させている/トップダウンとボトムアップのアプローチ/個人をよりインセンティバイズしてポテンシャルを開放させる仕組み 初回Podcastはこちら なぜ今web3なのか？（Why web3 now?） https://open.spotify.com/episode/2nhA9FQBhinfhYIv979BUQ?si=671dced51c944a07 公共財としてのAI、Cryptoの思想がAI時代に求められる理由 https://open.spotify.com/episode/4q2VUrQ3iCaF1iuq8n5XWZ?si=183422bc99154a56 Worldcoinとは？OpenAIのサムアルトマン氏によるもう一つのプロジェクト https://open.spotify.com/episode/4WZmWeAZqmVVu91fvP8Kaf?si=7c3a066eb5e6493c kinjo https://x.com/illshin AKINDO: https://x.com/akindo_io Miyata: https://x.com/miyata_17_ Seamoon Protocol JP: https://x.com/Seamoon_JP

IVC is a Web3 venture capital fund backed by leading Japanese gaming studios. They focus on Web3 gaming, digital entertainment, AI, DeFi, and infrastructure, and have invested in over 200 projects. They also host Japan's largest Web3 conference, IVS Crypto, which attracts over 12,000 attendees annually.Ann Chien serves as a Partner at IVC. She recently joined the Bitcoin.com News Podcast to talk about the Japanese Web3 market.Ann was previously a Director at HCM Capital, the venture arm of Foxconn Technology Group, specializing in blockchain and fintech investments. With experience in investment banking at Shenwan Hongyuan and equity research at BNP. Paribas, Ms. Chien brings a wealth of expertise to the blockchain investment field.

This week we delve into the world of the single ventricle when we speak with Dr. David Hoganson, Assistant Professor of Surgery at Harvard Medical School about a recent work he co-published with investigators from Boston Children's Hospital on computational fluid dynamic modeling in the planning of the Fontan operation. Single ventricle heterotaxy patients with interrupted IVC are at enhanced risk for the development of pulmonary AVM's due to flow maldistribution to the pulmonary arteries from the hepatic veins in a Fontan. Can a computational fluid dynamic model predict which operative approach would result in the most balanced hepatic venous flow distribution? Can this reduce the incidence of pulmonary AVM's? How well did the models predict the actual pulmonary flow measured after surgery on CMR? Who beyond the heterotaxy patient might benefit from this approach? Dr. Hoganson offers us a peek into the world of personalized surgery in this week's exciting episode.         DOI: 10.1016/j.jacadv.2024.101057

Summary In this week's episode, Anna (https://x.com/AnnaRRose) chats with Jens Groth (https://x.com/JensGroth16) and Daniel Marin (https://x.com/danielmarinq) from Nexus (https://nexus.xyz/). They catch up on all things Groth16 with the author himself before diving into a variety topics, such as formal verification in the context of ZKPs, the Nexus architecture, the benefits and challenges of building a system from the ground up, folding and IVC plus the properties these offer in a zkVM context and much more. Here's some additional links for this episode: ZKProof Conference in Berlin (https://zkproof.org/events/zkproof-6-berlin/) Nova: Recursive Zero-Knowledge Arguments from Folding Schemes by Kothapalli, Setty, and Tzialla (https://eprint.iacr.org/2021/370.pdf) Nexus zkVM (https://nexus.xyz/) Episode 284: Using Formal Verification on ZK Systems with Jon Stephens (https://zeroknowledge.fm/284-2/) Jens Groth Publication List (http://www0.cs.ucl.ac.uk/staff/j.groth/) Nexus Docs (https://docs.nexus.xyz/) Nexus 1.0 Machine (https://nexus.xyz/zkvm-v1) Enabling General-Purpose Verifiable Computing | Daniel Marin (Oct 2023) on YouTube (https://www.youtube.com/watch?v=G4ziNNC4zHM) Nexus 2.0 (https://nexus.xyz/zkvm) SETI@home (https://setiathome.berkeley.edu/) zkSummit12 is happening in Lisbon on Oct 8th! Applications to speak or attend are now open at zksummit.com (https://www.zksummit.com/), speaker applications close TODAY (Aug 14th) and early bird tickets for attendance are limited! Launching soon, Namada (https://namada.net/) is a proof-of-stake L1 blockchain focused on multichain, asset-agnostic privacy, via a unified shielded set. Namada is natively interoperable with fast-finality chains via IBC, and with Ethereum using a trust-minimized bridge. Follow Namada on Twitter @namada (https://twitter.com/namada) for more information and join the community on Discord (http://discord.gg/namada). Aleo (http://aleo.org/) is a new Layer-1 blockchain that achieves the programmability of Ethereum, the privacy of Zcash, and the scalability of a rollup. As Aleo is gearing up for their mainnet launch in Q1, this is an invitation to be part of a transformational ZK journey. Dive deeper and discover more about Aleo at http://aleo.org/ (http://aleo.org/). If you like what we do: * Find all our links here! @ZeroKnowledge | Linktree (https://linktr.ee/zeroknowledge) * Subscribe to our podcast newsletter (https://zeroknowledge.substack.com) * Follow us on Twitter @zeroknowledgefm (https://twitter.com/zeroknowledgefm) * Join us on Telegram (https://zeroknowledge.fm/telegram) * Catch us on YouTube (www.youtube.com/channel/UCYWsYz5cKw4wZ9Mpe4kuM_g)

השבוע היה לי הכבוד לארח את אבי אייל מ-Entrée Capital. Entrée Capital היא קרן הון סיכון גלובלית שהוקמה בשנת 2010. עם משרדי מטה בתל אביב, ישראל, ועוד משרדים בלונדון וניו יורק, החברה מנהלת למעלה מ-1.25 מיליארד דולר בתשע קרנות. Entrée Capital משקיעה במגוון רחב של תחומים בינהם AI, דאטה, Deep Tech, פינטק, סייבר, SaaS ועוד, ותומכת בסטארטאפים חדשניים משלבי pre-seed ועד שלבי צמיחה. פורטפוליו החברה הרחב כולל מעל 180 חברות בולטות, כגון Deliveroo, Coupang, Riskified ,monday.com, Rapyd, Talon Cyber, Coupang, HiBob, Gusto, Breezometer, Glovo, BlueWhite Robotics, Stripe, NVision, Stash, Mesh Payments, Perimeter81 and PillPack. חברות הפורטפוליו של Entrée Capital מגיעות לשווי כולל של מעל 335 מיליארד דולר ופועלות בשווקים גלובליים מגוונים כולל ארה"ב, בריטניה, אירופה, ישראל, אוסטרליה, אפריקה, הודו, ואיחוד האמירויות הערביות. Entrée Capital הצליחה להביא ליותר מ-33 אקזיטים והנפקות ציבוריות, עם הנפקות משמעותיות בשנת 2021, כולל Deliveroo, Cazoo, Coupang, Riskified ו-monday.com. עם 18 חברות יוניקורן בפורטפוליו, החברה מוכרת בזכות השפעתה המשמעותית והמנהיגות שלה בעולם הון הסיכון. הקרן דורגה כקרן הרביעית הבולטת ביותר באירופה על ידי Dealroom.co, הקרן הפעילה ביותר בישראל על פי IVC, ומייסד החברה, אבי אייל, נבחר להיות המשקיע המוביל באירופה ובמזרח התיכון ברשימת Forbes Midas Europe 2024.   (*) ללינקדאין שלי: https://www.linkedin.com/in/guykatsovich/ (*) לאינסטגרם שלי: https://www.instagram.com/guykatsovich/ (*) עקבו אחרינו ב"עוד פודקאסט לסטארטאפים" וקבלו פרק מדי שבוע: ספוטיפיי:https://open.spotify.com/show/0dTqS27ynvNmMnA5x4ObKQ אפל פודקאסט:https://podcasts.apple.com/podcast/id1252035397 גוגל פודקאסט:https://bit.ly/3rTldwq עוד פודקאסט - האתר שלנו:https://omny.fm/shows/odpodcast ה-RSS פיד שלנו:https://www.omnycontent.com/.../f059ccb3-e0c5.../podcast.rssSee omnystudio.com/listener for privacy information.

Ep 230 Johnathon Ivey Life of a Journeyman Johnathon Ivey is a lockeroom staple that has fought a whos who within the sport of MMA. We discuss some of his notable opponents as well as his roll in saving main events on the regional scene and navigating through some of the shadiest promoters in the business. Ivey is someone that carries a lot of respect within the closed doors of the locker room and this episode shows us why that is. Ep 230 Johnathon Ivey Life of a Journeyman 0:00 Lytes out intro0:19 guest introduction0:53 interview start 1:29 beginnings in MMA2:49 Pulled from audience to compete in event 5:24 experience with Jeff Osborne 6:26 early training partners 8:16 Johnathan Ivey vs Chad Bartlett 9:16 Jonathan Ivey vs Tyrone Roberts 9:53 100 fight club member Jeremy Horn10:08 thoughts on Jeremy Horn 12:36 experience fighting in Bushido15:00 saving MMA events 18:54 having locker room camaraderie 20:10 becoming a promoter21:26 Johnathan Ivey vs Pedro Otavio22:35 experience with Sergio Batarelli23:50 IVC remaining “no holds barred”25:59 night club story 27:45 traveling the world with the fight game 28:20 training with Dan Christison30:15 promoter Tom Stedham30:43 Jerome Smith 31:21 Eric Harvey 32:11 Jon Haskew33:14 wanting to coach High school Football 35:31 extreme challenge 46 8 man tournament 38:57 experience with Monte Cox 41:27 Johnathan Ivey vs Chris Mcstouts44:23 tapping out to save Travis Fulton 52:15 Johnathan Ivey vs Travis Fulton 55:00 promoter Brad Kohler59:17 Johnathan Ivey vs Ben Rothwell1:00:07 Felix Mitchell1:01:06 Chris Heflin1:02:05 Dave strasser's event 1:04:28 pride rules vs UFC rules1:06:33 Johnathan Ivey vs Justin Eilers1:08:19 Johnathan Ivey vs Andre Roberts1:09:26 Johnathan Ivey vs Gary Myers1:11:33 Chris Lytle getting stiffed on pay 1:13:14 John Dixson1:14:21 thoughts on Jonathan Wiezorek 1:15:37 Johnathan Ivey vs Dan Severn 1:17:07 Johnathan Ivey vs Jake O'Brian 1:18:59 advice to young fighters1:20:31 John Renken1:22:54 Mike Camp 1:25:05 100 fight club members 1:27:18 interview wrap up/ Outro Subscribe to the Lytes Out Podcast:https://www.youtube.com/@LytesOutClipsSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris - Founder/Owner - @chrislightsoutlytle Mike - MMA Detective - @mikedavis632 Joey - Assistant - @aj_ventitreTyson - Producer - @ty.green.weldingAndrew - Timestamps - @ambidexstressAndy - Social Media Manager - @martial_mindset_Outro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClub #MMAPodcast #FightPodcastSupport the Show.

In this episode of the Back Table Podcast, interventional radiologist Dr. Noor Ahmad discusses his algorithm for complex inferior vena cava (IVC) filter retrievals and reviews several cases that utilize various retrieval tools. --- CHECK OUT OUR SPONSOR Argon Medical http://www.argonmedical.com/ --- SYNPOSIS Dr. Ahmad emphasizes that most patients are referred by physicians with whom he maintains good relationships, and both specialties jointly monitor patients after IVC filters are placed. Generally, it is ideal to remove IVC filters around the 3-month mark, with filters in place for over 6 months posing a higher risk of requiring complex retrieval. For preoperative evaluation, obtaining a history of the filter type and placement date, along with CT scans (non-contrast and venogram), is crucial. Anticoagulation is typically discontinued two days prior to retrieval. During the procedure, moderate sedation and internal jugular access are used. However, complex retrievals may necessitate general anesthesia and access through the femoral vein or dual sites. The initial device employed is usually the CloverSnare to hook and extract the IVC filter. If unsuccessful, Dr. Ahmad proceeds with techniques such as the hangman (modified loop snare), endobronchial forceps, and finally the ClavaClear laser sheath. He highlights that particularly challenging cases might require collaboration with colleagues, especially when dual access is needed, possibly requiring rescheduling for general anesthesia availability. Patient safety is emphasized in these scenarios. Lastly, Dr. Ahmad presents past cases with imaging to illustrate various retrieval methods. --- TIMESTAMPS 00:00 - Introduction 03:29 - Referrals and Tracking for Filter Removal 08:49 - Working Up Complex Cases 13:19 - Patient Selection 20:14 - Procedure Walkthrough 23:22 - Different Strategies for Filter Removal 31:23 - Laser Techniques 34:47 - Sheath Sizing 36:06 - Enhancing Patient Safety 43:34 - Cheat Sheet for IVC Filters and Case Studies --- RESOURCES BackTable Ep. 204- Filter Indications and Filter Tracking: Up Your Game with Dr. Stephen Wang: https://www.backtable.com/shows/vi/podcasts/204/filter-indications-filter-tracking-up-your-game BackTable Ep. 339- The Importance of a Multidisciplinary Filter Retrieval Program with Dr. Robert Ryu, Dr. Warren Clements, and Dr. Premal Trivedi: https://www.backtable.com/shows/vi/podcasts/339/the-importance-of-a-multidisciplinary-filter-retrieval-program

Ep 227 Sergio Batarelli IVT 1996-98Sergio Batarelli was a world champion kick boxer that transitioned to being one of the pioneers of the No Holds Barred era. Sergio Batarelli's International Vale Tudo Championship was made famous for its 30 minute round and very few rules. Sergio is a legend within our sport and is a foundational father of the term No Holds Barred. 0:00 Lytes out intro0:19 guest introduction0:59 interview start 1:25 getting involved in fighting 3:10 Jiu Jitsu vs Martial Arts 4:50 roots of MMA5:15 not getting paid by Robson Gracie 6:33 pretending to be Italian 12:27 getting respect from Renzo Gracie 12:59 learning Jiu Jitsu from Flavio Behring14:57 experience with Carlson Gracie 16:07 current life/ personal training 18:16 bringing Vale Tudo to the United States22:59 Sergio Batarelli vs Duke Roufus24:30 Sergio Batarelli vs Mike Labree29:05 partnering with Frederico LapendaFor WVC31:13 WVC Japan 8 man Tournament 32:24 Marco Ruas and Rickson Gracie rivalry 34:38 Oleg Taktarov vs Marco Ruas 35:33 becoming the representative for Pride FC 37:48 Pedro Rizzo relationship with Marco Ruas 38:33 Oleg Taktarov vs Renzo Gracie 39:13 Refusing offer to fight Art Jimmerson 42:09 meeting a young Wanderlei Silva43:19 understanding match making 45:05 Fabio Gurgel vs Pat Smith46:25 introducing John Perretti to Wanderlei Silva 47:40 selling IVC library to the UFC 48:44 creating the “big daddy rule”51:36 Mark Kerr vs Sidney Goncalves Controlling the crowd 53:35 Fabio Gurgel vs Mark Kerr58:04 Pele vs Johil De Oliveira 1:03:03 creating the Vale Tudo confederation1:03:55 splitting up with Frederico Lapenda1:05:20 IVC doctors checking fighters while keeping position 1:07:04 Ebenezer Braga1:08:10 Sean Bormet vs Wanderlei Silva1:11:48 Wanderlei Silva proposing loser gets no money1:13:19 predicting Mirko Cro Cop's success 1:17:30 Montanha Silva story 1:21:26 Pentagon Combat riot 1:22:41 getting Carlson Gracie's guys to fight 1:24:53 Luta Livre BJJ Rivalry1:29:18 Pacatau 1:29:42 Bob Schrijber vs Wanderlei Silva1:30:23 dealings with high ups 1:32:06 fighters respecting eachother 1:33:04 becoming the go to guy for problem solving 1:35:34 Vitor Belfort claiming he was drugged before fight 1:35:55 Kazushi Sakuraba vs Ebenezer Braga1:36:13 Problem with Mark Coleman at a show 1:38:22 Edson Carvalho and Marco Ruas and Walid Ishmael arguing 1:40:02 first recorded head stomp 1:43:00 interview wrap up 1:43:36 outro/ closing thoughts Subscribe to the Lytes Out Podcast:https://www.youtube.com/@LytesOutClipsSocials: Facebook -https://www.facebook.com/groups/1027449255187255/?mibextid=oMANbwInstagram - https://www.instagram.com/lytesoutpodcast/iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Mike - The MMA Detective - @mikedavis632 Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Follow the #LOP team on Instagram: Chris - Founder/Owner - @chrislightsoutlytle Mike - MMA Detective - @mikedavis632 Joey - Assistant - @aj_ventitreTyson - Producer - @ty.green.weldingAndrew - Timestamps - @ambidexstressOutro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MikeDavis #MMAHistory #OldSchoolMMA #FiftyFightClubSupport the Show.

Dublin-based FIRE1 today announced that the first Irish patient has been successfully implanted with its FIRE1 System for remote heart failure monitoring. The innovative system has the potential to positively impact thousands of people living with heart failure in Ireland every year and alleviate the burden on hospital emergency rooms. The successful implantation took place at University Hospital Galway in the First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF). The study will assess FIRE1's novel solution to improve outcomes for those living with heart failure. Irish medtech company FIRE1, whose CEO, Conor Hanley, was recently announced as a 2024 EY Entrepreneur of the Year finalist, seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a device at home, similar to how continuous glucose monitoring transformed diabetes care. Fluid overload is a classic clinical feature of heart failure, which affects approximately 90,000 Irish people and is a leading cause of hospitalisations, including high admission and re-admission rates in Ireland. FIRE1 CEO and President Conor Hanley said, "I am especially pleased to announce our first patient in Ireland. This represents a true clinical research success for Ireland, being one of the first systems of its nature to be developed, manufactured, and now in a clinical trial in Ireland. It showcases Ireland's capability for groundbreaking medical innovation with the potential to change healthcare delivery globally. The FIRE1 team is steadfast in our mission to help millions of people around the world living with heart failure to get their normal lives back, but it is very special to be able to give access to people here at home. It is gratifying to see the physician interest in our novel technology. I would like to extend my thanks on behalf of the whole FIRE1 team to the fantastic staff at UHG, and most importantly to the patients who continue to put their trust in us and participate in this important research." The FIRE1 sensor is implanted into the body's largest vein, located in the abdomen, known as the inferior vena cava (IVC) and works by continuously measuring the size of the IVC, giving a marker of the amount of fluid in the body. High levels can increase the risk of breathing difficulties and a build-up of fluid in the lungs, which lead to an emergency hospital admission. The patient wears a belt reader around the abdomen for around a minute a day to take a reading from the sensor and the data is sent to the patient's clinical team at the hospital. The system is designed to alert whenever the patient's condition deteriorates. Professor of Interventional Cardiology and Translational Medicine at University Hospital Galway (UHG), Prof Faisal Sharif performed the implant. "We are delighted to bring this new, transformative technology to Ireland for the first time," said Prof Sharif. "The procedure was very straightforward, minimally invasive and the patient was confident using the FIRE1 system and taking the readings. The data we will get from this patient will give a new window into heart failure management and has the potential to dramatically improve our understanding of this patient's condition, and to enable proactive changes in medications that will keep them healthy and at home. We hope to implant further patients at UHG while recruitment is still active."

On today's episode, I cover a 12-1 senior night win for #2 Metamora over IVC in six innings. The episode features a stat rundown from the game, as well as interviews with Redbird players Addi Pacha and Hannah Yoder, as well as coach Deric Linder. I also break down the Limestone-Canton, Dunlap-Pekin, and Washington-Galesburg games. Enjoy!

Dive into something truly enlightening by tuning in to our latest podcast episode. Dr. Joseph Cullen, a distinguished Professor of Surgery at the University of Iowa Carver College of Medicine, unveils the remarkable findings from his pioneering phase 1 and phase 2 clinical trials, where high-dose vitamin C (IVC) is combined with standard care medications for cancer patients.Discover how his groundbreaking randomized IVC trial with pancreatic cancer patients is reshaping the landscape of cancer treatment, showing promising results in significantly extending the lives of patients with this terrible disease.Dr. Cullen will also shed light on ongoing IVC research with glioblastoma, non-small cell lung, rectal, breast, prostate, and other cancers. Don't miss this opportunity to learn from one of the leading figures in cancer research.

On today's episode, I take you through an exciting 2-1 win for 3A #3 Metamora over 3A #5 Pontiac, featuring interviews with head coach Deric Linder, Nora Johnson, and Bailee Bender. I also discuss a 4-0 win for the Limestone Rockets at IVC. Enjoy!

The Indus Valley Civilization is one of the most enigmatic, sophisticated, and compelling ancient societies. For seven centuries, it thrived in the western portions of South Asia, building enormous mud-brick cities without domination by ruling kings or elites. But then, over the course of several hundred years, the IVC slowly disintegrated. Why?Patrick's book is now available! Get The Verge: Reformation, Renaissance, and Forty Years that Shook the World in hardcopy, ebook, or audiobook (read by Patrick) here: https://bit.ly/PWverge. And check out Patrick's new podcast The Pursuit of Dadliness! It's all about “Dad Culture,” and Patrick will interview some fascinating guests about everything from tall wooden ships to smoked meats to comfortable sneakers to history, sports, culture, and politics. https://bit.ly/PWtPoDListen to new episodes 1 week early, to exclusive seasons 1 and 2, and to all episodes ad free with Wondery+. Join Wondery+ for exclusives, binges, early access, and ad free listening. Available in the Wondery App https://wondery.app.link/tidesofhistorySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the final meditation of the Spiritual Exercises, St. Ignatius of Loyola reminds us “that love ought to manifest itself in deeds rather than in words.” We are called to love and serve in all things. And so, it's hardly a surprise that in the 500 or so years since Ignatius wrote those words, countless service organizations have grown and flourished within the Ignatian tradition. Over the course of the next two weeks, we're going to explore two of those organizations. Today, we're talking about the Ignatian Volunteer Corps with President and CEO of IVC, Mary McGinnity. Mary has more than 30 years of experience in leadership positions in education, faith formation, pastoral counseling, parish ministry and faith-based non-profit social justice and service organizations. She's a graduate of the College of Holy Cross and served as a Jesuit Volunteer. Most importantly, Mary is passionate about integrating service and justice. Today's host Eric Clayton has had the privilege of traveling to a number of IVC communities and meeting countless Ignatian volunteers. These are remarkable women and men who bring to their service experience a whole career worth of knowledge, insights, skills and networks. And they offer all of these invaluable resources to local nonprofits, bolstering the capacity of communities to respond to some of the most pressing needs of our time. What's more, IVC is a lay-led organization that is empowering lay leaders. In many ways, IVC is helping all of us envision what it means to be Church — especially as we all try to live the ongoing lessons of the Synod on Synodality. If you're interested in learning more about IVC, visit IVCUSA.org.

Maikel García considera que lo que hizo fue gozarse el batazo y en ningún momento consideró sus gestos como una provocación. Esto se lo confesó el pelotero al periodista Carlos Valmore Rodríguez, a tavés de las pantallas de IVC, una vez finalizado el compromiso. «Creo que me estaban gritando del dugout (del Cardenales) que estaba asustado. Y la verdad es que yo soy un pelotero que pienso que nací para estos momentos. Bueno y me lo disfruté. Uno no vive esto todos los días y disfrutando al máximo con los fanáticos que me transmiten esa energía». Maikel García considera que no estaba azuzando a nadie con sus gestos emotivos, luego de sacar la pelota. «De verdad es que yo no traté de provocar a nadie», confesó el toletero. «Fue un batazo importante que sirvió para darle la victoria al equipo en ese momento». «No trato de ofender a ningún rival y solo me dejé llevar por la emoción», soltó el slugger al periodista. El toltero de los Tiburones dijo que el próximo juego será uno más para ellos y cuando se le preguntó si esto cambiaría el tono de la serie fue claro al respecto. «No sé si cambiará algo», explicó. «Sólo sé que mañana (este jueves) nosotros vamos a llegar al terreno a jugar como siempre lo hacemos y a hacer las cosas pequeñas para ganar el tercer juego». Entrevista a Maikel García --- Send in a voice message: https://podcasters.spotify.com/pod/show/alfredo-villasmil/message

Dr. Jimenez is the Founder and Head of the OncoProteomics Laboratory and Professor of “Translational OncoProteomics” at the VU University Medical Center in Amsterdam. The focus of our conversation is her comprehensive 2021 research summary, “High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer,” published in the Journal of Experimental & Clinical Cancer Research. This pivotal work offers tumor site-specific information, as well as cancer drug-specific information, making it an invaluable resource for patients seeking relevant and personalized insights.Listeners will gain an in-depth understanding of the optimal dose levels of IVC used in research studies, crucial for achieving effective use of the therapy. Moreover, Dr. Jimenez elucidates the mechanisms of action of IVC, including its ability to reactivate tumor suppressor genes, which play a critical role in cancer prevention and treatment.

CardioNerds meet with fellows from The Christ Hospital, Drs. Hanad Bashir, Hyunsoo Chung, and Dalia Aziz to discuss the following case that highlights angioleiomyoma: A 60-year-old woman with a past medical history significant for breast cancer (on tamoxifen) presented as a transfer to our facility for a clot-in-transit. She had initially presented to the outside hospital after progressive dyspnea on exertion and recent syncope. She was found on an echocardiogram to have a right atrial mass spanning into the right ventricle. CTA of the chest and abdomen/pelvis demonstrated extensive thrombus burden spanning from the IVC into the right ventricle. She was transferred to our facility for intervention. Endovascular attempts were unsuccessful, at which point she underwent surgical thrombectomy. Gross examination of the mass revealed a cylindrical shape, homogeneous tan color, rubbery soft tissue, measuring 25.5 cm in length and 2.3 cm in diameter. Histology confirmed the presence of angioleiomyoma. A second, smaller mass (5.2cm long and 4mm in diameter) was removed from under the tricuspid valve, with histology consistent with leiomyoma. Estrogen receptor and progesterone receptor staining were strongly positive, leading to the discontinuation of tamoxifen. Given the presence of uterine fibroids identified on the CT scan, there was concern about a uterine origin. A hysterectomy is planned for her in the near future. Expert commentary is provided by Dr. Wojciech Mazur. Episode audio was edited by student Dr. Adriana Mares. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - The Tall Tail Heart: Angioleiomyoma – The Christ Hospital Pearls - The Tall Tail Heart: Angioleiomyoma – The Christ Hospital Although evaluation of cardiac mass by echocardiography can provide information such as size, location, and morphology, adjunctive cross-sectional imaging may be used depending on the need for further temporal resolution (CT) or tissue characterization via cardiac MRI (CMR). If suspicious for elevated metabolic activity, there should be consideration of FDG-PET. Tamoxifen (a selective estrogen receptor modulator) is an agent used for breast cancer therapy. However, its use has been associated with endometrial hyperplasia, uterine fibroids, endometrial and uterine malignancy. Increased risk of malignancy has been seen more often in post-menopausal women and is dose and time-dependent. Clot in transient is a mobile thrombus, typically within the right heart structures. It is estimated to occur in 4-18% of patients with pulmonary embolism and is associated with elevated morbidity and mortality. Treatment includes surgical embolectomy, endovascular embolectomy, systemic thrombolysis, catheter-directed thrombolysis, or systemic anticoagulation. Angioleiomyoma is a rare benign pericystic tumor that most commonly affects the extremities. There are case reports of other affected sites, including the uterus. Invasion into the cardiac structures is exceedingly rare. The only established treatment for angioleiomyoma is surgical resection. Show Notes - The Tall Tail Heart: Angioleiomyoma – The Christ Hospital Syncope Syncope is a transient loss of consciousness secondary to reduced blood flow to the brain. Often, certain presentations are mislabeled as syncope, such as seizure disorders, posttraumatic loss of consciousness, and cataplexy. An organized diagnostic approach should be used to reduce hospital admissions and medical costs and increase diagnostic accuracy. Syncope can be divided into five general subgroups. 1) Neurally mediated reflex syncope (carotid sinus syndro...

In this episode of CTSNet's flagship podcast, editor in chief Joel Dunning runs through the latest, most popular content on ctsnet.org—the largest online community of CT surgeons and source of CT surgery information—and breaking cardiothoracic surgery news and research from around the world. Joel discusses the outcome of the second genetically modified pig heart transplant, a meta-analysis of reconstructed data from the TAVR trial, and perioperative Durvalumab for resectable non-small cell lung cancer. He also talks about a video demonstrating left atrial aneurysm repair by IVC transection and a video demonstrating surgical repair of a double aortic arch through a sternotomy. After discussing upcoming events in the CT surgery world, he closes with a shoutout to the CT surgeons he worked with during his recent trip to UGMC Hospital in Accra, Ghana. JANS Items Mentioned World's Second Genetically Modified Pig Heart Transplant Patient Dies  Midterm Survival of Low‐Risk Patients Treated with Transcatheter Versus Surgical Aortic Valve Replacement: Meta‐Analysis of Reconstructed Time to Event Data  Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer  CTSNet Content Mentioned Left Atrial Aneurysm—Approach by IVC Transection Surgical Repair of Double Aortic Arch Through Sternotomy Other Items Mentioned CTSNet Events Calendar Arrhythmia Alliance Mission to Ghana Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

This week our host Brandi Starr is joined by Eileen Page, Senior Vice President of Digital Solutions and Innovation at InVision Communications (IVC). Eileen spearheads IVC's digital and technology innovation team, ensuring digital activations and experiences are executed to the highest standards. With 20+ years of expertise crafting break-through digital solutions for Fortune 1000 brands, she fuses strategy, creativity, and technical insight to create proprietary technology (apps, custom CMS) installations, virtual experiences, and digital campaigns for brands like DuPont, Siemens, Amway, Dell Technologies, and Oracle. On the couch in this weeks' episode of Revenue Rehab, Brandi and Eileen will tackle Events Reimagined: How AI is Shaping the New Normal in Experiences. Links: Get in touch with Eileen Page on: LinkedIn Instagram Subscribe, listen, and rate/review Revenue Rehab Podcast on Apple Podcasts, Spotify, Google Podcasts , Amazon Music, or iHeart Radio and find more episodes on our website RevenueRehab.live

This week on BackTable Urology, Dr. Aditya Bagrodia (UCSD), medical oncologist Dr. Rana McKay (UCSD) and radiation oncologist Dr. Shankar Siva (University of Melbourne) discuss the growing role of radiation therapy in kidney cancer treatment. --- SHOW NOTES Shankar first explains the original historical studies that provided evidence of the limited efficacy of low dose conventional radiation therapy (RT) in treating kidney cancer. However, he and Rana discuss how stereotactic body radiation therapy (SBRT), a newer technology which delivers a higher dose per fraction more accurately, has shown better outcomes in clinical trials than conventional RT. They also explain the associated risks with SBRT and how neoadjuvant therapies can be combined with radiation. They also consider the use of SBRT in bulky tumors and those with IVC thrombus. All three doctors agree that radiation therapy needs to be incorporated into a multimodal approach to kidney cancer. They also discuss the potential of radiation therapy in the cytoreductive setting and its role in delaying systemic therapy in patients with oligometastases. Finally, they explore the possibility of using PET imaging to detect oligometastatic disease. Although prostate-specific membrane antigen positron emission tomography (PSMA PET/CT) imaging is mostly used to stage prostate cancer, other solid tumors like renal cell carcinoma (RCC) may also express PSMA. For this reason, they agree that a next generation PSMA PET/CT equivalent for RCC could be revolutionary. Lastly, they predict what the future of RCC could hold by examining newer therapies, such as radioligand therapy and cyberknife. --- RESOURCES Kidney Cancer Association: 2023 International Kidney Cancer Symposium (Nov. 9-11) https://www.kidneycancer.org/ikcs/2023-ikcs-north-america/ Decipher by Veracyte https://decipherbio.com/ WellPrept https://wellprept.com/

We're getting ready for a Week 7 Three Rivers Conference Mississippi Division game between the Hall-Putnam County and Newman football teams. Newman is the first of three ranked teams the Red Devils end their regular season with. Coach Randy Tieman talks about the Week 6 win over IVC and today's battle against Newman. Tune into The Wolf 96.5 FM as the pregame starts at 12:45 p.m. and kickoff is at 1 p.m. Listen to Brandon LaChance and Jeremy Aitken with the call.

"The primary safety and primary efficacy endpoints—which were preset in consideration with the FDA and all the societies—were met. You look at what we did, what we said, and using those definitions, filters are safe and effective."—Matthew S. Johnson, MD, FSIR, PRESERVE Principal InvestigatorHost Warren Krackov, MD, FSIR, speaks with PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) Trial Principal Investigator Matthew S. Johnson, MD, FSIR, about the lessons learned from the trial's initial data, his collaboration with vascular surgery and others in the study, and more. Related resources:Predicting the safety and effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months (Journal of Vascular and Interventional Radiology, April 2023)SIR/SVS Press Release on PRESERVE (Feb. 23, 2023)"Session recap: The SIR/SVS PRESERVE Trial" (SIR Today, March 6, 2023)Episode 10: The ongoing evolution of IVC filters (June 30, 2020)Note: This episode was recorded on Aug. 8, 2023.Support the show

O programa dessa semana recebe o veterano Johnny Eduardo. Aos 45 anos de idade, ele conversou com Marcelo Russio e Gleidson Venga e relembrou o começo da carreira no muay thai, suas lutas no IVC, Shooto e UFC, comentou sobre os eventos russos e revelou que ainda não se aposentou do MMA - está com uma luta programada para este ano, contra um atleta ex-UFC e que ele já desafiou no passado. Quem será?

Vitamin C is a potent anti-cancer agent in high doses, helping to boost immune response and suppress the proliferation of cancer cells. Join me as I speak with Dr. Lucas Tims, ND, FABNO, as we delve into the science surrounding the use of high-dose vitamin C as an adjunctive therapy for cancer treatment. What you'll learn from this episode:The mechanisms by which high dose vitamin C works to fight cancerProper dosing & how to tell if you're getting enoughWhy intravenous vitamin C is more powerful than oral supplementationWhat to look for in the sourcing/quality of the vitamin CComplementary therapies that work synergistically with IVC& Much more!Resources:Dr. Lucas Tims | WebsiteDr. Lucas Tims | InstagramIVC research studies To learn more about WellnStrong: Subscribe to my newsletter! WellnStrong Blog WellnStrong Instagram WellnStrong Pinterest

In this episode, guest host Dr. Robert Ryu interviews Dr. Warren Clements and Dr. Premal Trivedi about the current state of IVC filter retrievals, obstacles to increasing retrieval rates, and their experiences with implementing programs to increase IVC filter retrieval rates within their respective healthcare systems. --- CHECK OUT OUR SPONSOR Boston Scientific Lab Agent https://www.bostonscientific.com/en-US/customer-service/ordering/lab-agent/contact.html?utm_source=oth_site&utm_medium=native&utm_campaign=pi-at-us-labagent-hci&utm_content=n-backtable-n-backtable_site_labagent_1_2023&cid=n10013205 --- SHOW NOTES Dr. Clements begins the discussion by giving an overview of his recent paper published in CVIR, which explores a novel multidisciplinary approach to IVC filter retrievals. He introduces key features of the Australian healthcare system that contribute to their strengths and challenges with IVC filter retrievals. Dr. Clements emphasizes the positive correlation between maintaining an active database of all IVC filter patients and increased retrieval rates. He discusses the limitations of their previous approach towards IVC filter retrievals, which relied on referring physicians and an automatic retrieval referral system. This passive model posed issues with timing and led to a lower retrieval rate. He also highlights the differences in governmental oversight and filter utilization between Australia and the US, emphasizing the importance of aiming for a 100% retrieval rate. The new approach at his hospital involves a multidisciplinary team, which has resulted in retrieval rates going from 53% to 74% . Next, Dr. Trivedi discusses his recent paper, which is also focused on quality improvement surrounding IVC filter retrieval. He describes his health system's previous passive approach that relied on a follow-up list of all patients with IVC filters. The list was checked monthly, and letters were sent to patients providing the status of their filters along with educational material. However, since 2016, they have adopted an active methodology, which relies on the IR team actively evaluating the list of patients with an IVC filter and verifying whether retrieval is appropriate in each case. This active approach engages referring doctors and schedules retrievals as needed. Implementing this new methodology has resulted in an increase in IVC retrieval rates from 49% to 61%. The doctors discuss the significant number of filters placed before 2010 that still need to be retrieved. They emphasize the need for a central dedicated team to take responsibility for filter follow-up and retrieval, and they highlight potential role of AI in automating the process and addressing issues related to patients who are lost to follow-up. Finally, they discuss the future of filter retrieval. Both Dr. Clements and Dr. Trivedi stress the importance of knowing the IVC retrieval rate to set goals accordingly. Dr. Clements shares his team's goal of reducing median dwell time to less than 150 days and the benefits of establishing a national registry. Dr. Trivedi emphasizes the need for incremental goals and celebrating small wins on the path towards increasing overall filter retrieval rates. He also discusses the importance of aligning economic and health incentives and leveraging existing AI technology. They all agree that achieving a 100% filter retrieval rate requires a collaborative effort within a multidisciplinary team. --- RESOURCES “Improving the rate of inferior vena cava filter retrieval through multidisciplinary engagement” by Clements et al: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958400/ “Inferior Vena Cava Filter Retrieval Rates Associated With Passive and Active Surveillance Strategies Adopted by Implanting Physicians” By Trivedi and Ryu et al: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802524

I'm giving away a Lifetime Membership to the Introvert VA Club!

Track Listing:1 Nielsen: Symphony No. 1 in G Minor, Op. 7: / I. Allegro orgoglioso 09:202 II. Andante 07:473 III. Allegro comodo 07:494 IV. Allegro con fuoco 08:58 5 Symphony No. 2, Op. 16 The Four Temperaments / I. Allegro collerico 10:066 II. Allegro comodo e flemmatico 04:567 III. Andante malincolico 12:568 IV. Allegro sanguineo 07:02 9 Symphony No. 3, Op. 27 Espansiva / I. Allegro espansivo 11:0910 II. Andante pastorale 10:3811 III. Allegretto un poco 06:4312 IV. Finale. Allegro 10:52 13 Symphony No. 4, Op. 29 The Inextinguishable / I. Allegro 12:2114 II. Poco allegretto 04:3215 III. Poco adagio quasi andante 10:4716 IV. Allegro 08:51 17 Symphony No. 5, Op. 50: Ia. Tempo giusto 10:2918 Ib. Adagio 08:5219 IIa. Allegro 06:1420 IIb. Presto 02:5821 IIc. Andante poco tranquillo 04:2022 IId. Allegro 02:5623 Symphony No. 6 Sinfonia Semplice / I. Tempo giusto 14:2724 II. Humoreske 04:1125 III. Proposta seria 05:2726 IVa. Allegro – Tema. Allegretto un poco 00:5827 IVb. Var. 1 00:3228 IVc. Var. 2. Allegretto quasi andantino 00:2829 IVd. Var. 3. Più vivo – Var. 4. – Var. 5. Brioso 02:1730 IVe. Var. 6. Tempo di Valse – Var. 7 02:1131 IVf. Var. 8. Molto adagio 03:0232 IVg. Var. 9. Tempo di tema 00:2833 IVh. Fanfare 01:44Help support our show by purchasing this album  at:Downloads (classicalmusicdiscoveries.store) Classical Music Discoveries is sponsored by Uber and Apple Classical. @CMDHedgecock#ClassicalMusicDiscoveries #KeepClassicalMusicAlive#CMDGrandOperaCompanyofVenice #CMDParisPhilharmonicinOrléans#CMDGermanOperaCompanyofBerlin#CMDGrandOperaCompanyofBarcelonaSpain#ClassicalMusicLivesOn#Uber#AppleClassical Please consider supporting our show, thank you!Donate (classicalmusicdiscoveries.store) staff@classicalmusicdiscoveries.com This album is broadcasted with the permission of Crossover Media Music Promotion (Zachary Swanson and Amanda Bloom).

In this episode, host Dr. Aparna Baheti interviews Dr. Fritz Angle about adrenal vein sampling, including indications, workup, and his technique for accessing the right adrenal vein. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES Dr. Fritz Angle is the Director of Interventional Radiology at the University of Virginia. He frequently performs adrenal vein sampling for primary hyperaldosteronism, and has developed a specific technique. The patient is usually referred from an endocrinologist or primary care doctor. The IR should review the labs to verify the aldosterone-to-renin ratio is greater than 20. Additionally, it is important to review medications and stop all potassium sparing diuretics at least two weeks before the procedure. If they haven't had a CT scan, the IR should order one to assess the position of the right adrenal vein, the hardest to access due to its variable anatomy.  The morning of the procedure, Dr. Angle always checks a potassium level to know whether to give potassium supplements. He gets dual femoral access, so that he can obtain both non-stimulated and ACTH-stimulated samples. He obtains the sample from the left adrenal vein first. For the right side, he starts with a C2 catheter, to which he adds side holes using a biopsy needle. The left adrenal vein is almost always one vertebral body above the right renal vein, so he begins here, with the catheter pointing directly posterior. He searches around the entire back wall of the IVC by puffing contrast and rotating the catheter. He moves up and down by half a vertebral level. If he still cannot locate it, he begins looking to the left and right. When injecting, it is important to be gentle. To do this, he inserts an 014 wire through his catheter, then does a dry scan to see if the vein is pointing toward the liver or the right adrenal gland. If the vein is injected too hard, it can cause a venous infarct and adrenal insufficiency. The right adrenal vein forms an upside down Y shape. Dr. Angle draws two sets each from the right and left adrenal veins and two peripheral samples.  To interpret results, look for a cortisol of 2-3x greater (3-4x greater in stimulated samples) compared to the peripheral blood to confirm correct placement in the adrenal veins. Once you correct aldosterone levels to cortisol levels, the aldosterone-to-cortisol ratio should be about 5x greater on one side (compared to the other side) to confirm the diagnosis and lateralize the hyperaldosteronism to one side. About 2 ⁄ 3 cases lateralize, but Dr. Angle has found many patients' symptoms are actually due to bilateral adrenal hyperplasia. Finally, Dr. Angle emphasizes that this is an easy, safe procedure that all IRs should offer.

Measurement of intravascular volume has only recently studied, covering the use of diuretics and filtration during dialysis.Dr Matthew Kaptein of Loma Linda University reviews available evidence that may validate the IVC collapsibility index for measuring relative intravascular volume. He has developed a calculator tool which will help doctors navigate this important step for optimizing the intravascular volume of their patients to offer more effective treatments.  Learn more about Kaptein's Calculator Tool: Calculator Tool

Full article: https://www.ajronline.org/doi/10.2214/AJR.22.28142  Filter specialized referral centers have grown under the spotlight of complex filter retrievals. Abdul Khan, MD, discusses a recently published AJR article in which investigators analyze the success rate and predictors of adverse events of complex IVC filter retrieval at a large, specialized referral center.

 Francisco Bueno - Career DEEPDIVE (ep, 145)#FranciscoBueno #MMAHistory #bjj Brazilian Jiu Jitsu coral belt Francisco Bueno joins the #LytesOut team to talk about his fighting career, dating bck to the 1990's. Now a coach, Bueno fought MMA in the IVC and Pride back in te day and we will ask more about his times as a competing black belt.Subscribe to the Lytes Out Podcast: https://www.youtube.com/channel/UCnyrswDJ9PkNHqFLOMfIdZw Also, don't forget to join our clips channel for more short-form content - https://www.youtube.com/channel/UCdcebSeWpoMqcotWR_1rHnQ Socials: Instagram - https://www.instagram.com/lytesoutpodcast/ iTunes - https://podcasts.apple.com/us/podcast/lytes-out-podcast/id1568575809 Spotify - https://open.spotify.com/show/3q8KsfqrSQSjkdPLkdtNWb Facebook - https://www.facebook.com/LytesOutPodcast/ Cash App - $mikedavis1231Venmo - Mike-Davis-63ZELLE: Cutthroatmma@gmail.com / ph#: 773-491-5052 Patreon - Lytesoutpodcast@gmail.comThanks for listening to Francisco Bueno - Career DEEPDIVE (ep, 145)Follow the #LOP team on Instagram: Chris - @chrislightsoutlytle Mike - @mikedavis632 Miguel - @iturratemOutro song: Power - https://tunetank.com/t/2gji/1458-power#MMA #UFC #NHB #LytesOutPodcast #LytesOut #MixedMartialArts #ChrisLytle #MMADetective #MiguelIturrate #MikeDavis #MMAHistory #OldSchoolMMA #FightPodcast #FightTalk #DEEPDIVE #FiftyFightClub #MMAPodcast #FightPodcast Support the show

Cancer is as unique to a person as a fingerprint. Why not receive cancer care that is unique and individualized to you? You've heard about IV-C, turmeric, CBD and Medical MMJ to treat cancer but how do you put it all together. Now you can Brio-Medical is not only treating rare, aggressive and late stage...

In this episode Garth interviews Jerry Rudman from Irvine Valley College in Irvine, CA.  Spanning six decades, Jerry has been devoted to undergraduate education through many venues.  He has contributed to APA Guidelines 1.0, 2.0, and the forthcoming 3.0 revision, as well as part of the P3 Conference and the Introductory Psychology Initiative (and more). When he starts a Psi Beta chapter at IVC in 1992, the fortunes dramatically improved for Jerry and for his students.  Jerry comes from humble beginnings as a first-generation college student and then working in human factors in the aerospace industry.  Like so many other legends in psychology, the content of the introductory psychology course truly drew Jerry's attention to the discipline. You can learn more about Psi Beta at https://psibeta.org/  

Question: What does a packet of M&M's and your local veterinarian have in common? Answer: Both are owned by Mars Inc., the global candy monopolist. Since the 1980s, we've seen massive consolidations in industry after industry – from airlines to newspapers, the internet to candy. These monopolists run roughshod over consumers, workers, communities, suppliers, and our nation's commitment to the Common Good. And now the corporate attitude seems to be, “what the Hell, why not let monopolization go to the dogs?” This change has been led by “private equity groups.” They are corporate-takeover sharks that borrow billions of dollars to buy out, plunder, then sell off the remnants of established businesses. They target enterprises that can be grabbed on the cheap but have assets like a loyal customer base. Then the sharks raise prices on those customers while cutting staff and quality of service. This has been happening to thousands of local vet practices and hospitals, which have quietly been plucked by Wall Street entities bearing non-descript acronyms like IVC, JAB, KKR, and VCA. At first locals don't notice the takeover, because the corporate outfit not only buys your friendly “Dr. Barry Bones” vet service, they also buy the Doc's name. As an IVC takeover consultant confided: “People like to take their dog to local vets and not feel like it's a corporate machine.” But increasingly, it is. Solo practitioners who became veterinarians to provide friendly, community-based service now must answer to bean counters at headquarters – and, foremost, they must serve profit over animals. Veterinary Center of America (VCA), for example, is one of the most aggressive monopolizers, controlling access to and prices charged by 1,000+ vet facilities in 43 states. In 2017, VCA was taken over by Mars Inc. One feisty group battling monopolizers is the National Veterinary Professionals Union – Get info at natvpu.org.

In this episode of We Are Vineyard, Jay talks with Bubba Justice about his formational experiences of being raised in poverty by a single mother and visiting his grandmother's homeless shelter, his first experiences with the Holy Spirit, and how his education in finance turned out to be an asset in ministry. Bubba shares about his goal of planting churches throughout the world that are self-sustaining, and some exciting collaborative opportunities in international missions. Finally, Bubba offers an encouragement to pastors to dream about missional opportunities both “near and far”. Elgie “Bubba” Justice is the Chief Financial Officer and Missions Coordinator for Vineyard USA. In his capacity as the Missions Coordinator, he gives leadership to VUSA Missions by overseeing mobilization, training, partnership development, and coordinating US activity with Vineyard associations internationally. As CFO, he oversees the financial and human resource systems for the Vineyard Movement in the United States. Prior to this role, Bubba served as the National Coordinator for Vineyard USA for four years, starting in 2017 under the leadership of Phil Strout. Over the years, Bubba has served in Vineyard Leadership on the Executive Team, Vineyard Resources Board, Vineyard Worship Board, and on the Multiply Vineyard Advisory Team. After working in the financial world as a C.P.A., a financial manager, and a chief financial officer, Bubba was the senior pastor of the Inverness Vineyard Church (IVC)for 23 years. Before planting IVC, Bubba served in many roles as a volunteer pastor in the Birmingham Vineyard from 1983 until 1993. Some of the ministries Bubba led included youth, children, nursery, intercession, small groups, and ministry team. Bubba and his wife Melany live in Houston, TX, and have two married daughters and one grandchild. Show Notes: Vineyard USA suggested reading for September Prophetic Lament by Soong-Chan Rah https://vineyardusa.org/podcast/ Compassion International https://www.compassion.com/ Convoy of Hope https://convoyofhope.org Petros Network https://petrosnetwork.org Socials: Vineyardusa.org @vineyardusa

CardioNerds (Amit Goyal and Dan Ambinder) join Dr. Radi Zinoviev, Dr. Josh Cohen, and Dr. Tiffany Dong (CardioNerds Ambassador) from the Cleveland Clinic for a day on Edgewater beach. They discuss the following case of the evaluation and management of prosthetic tricuspid valve stenosis in a patient with a history of Ebstein Anomaly. The expert commentary and review (ECPR) is provided by Dr. Jay Ramchand, staff cardiologist with expertise in multimodality cardiovascular imaging at the Cleveland Clinic. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. This episode is made possible with support from the 3rd Annual Going Back to the Heart of Cardiology (A MedscapeLIVE Conference). Join Dr. Robert Harrington and Dr. Fatima Rodriguez December 3-5, 2022 at the Hilton La Jolla Torrey Pines in San Diego, CA for this innovative event. Network with your colleagues, attend engaging presentations by renowned cardiologists, participate in conference activities, and earn up to 10.25 CME/CE credits. You don't want to miss the keynote presentation by health and fitness expert Bob Harper (NBC's The Biggest Loser). Earn up to 3.0 additional CME/CE credits by adding this year's NEW Virtual Interventional Session: Cath Lab Challenge to your conference registration. Register today with code CARDIONERDS for 30% OFF your registration. Click here for more information. Jump to: Case media - Case teaching - References CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media CXR ECG TTE RHC Final TTE TTE 1 TTE 2 TTE 3 Follow up TTE 1 Follow up TTE 2 Episode Schematics & Teaching Pearls - Tricuspid Valve Stenosis Tricuspid stenosis is uncommon ( 60cm.Structural findings that support the presence of severe tricuspid stenosis include a moderately dilated RA and a dilated IVC, though these are not specific.Right heart catheterization hemodynamics that support tricuspid stenosis include a high right atrial pressure and gradual “y” descent.Bioprosthetic tricuspid valves are generally favored over mechanical valves due to risk of thrombosis and longevity of these valves in the tricuspid position. Notes - Tricuspid Valve Stenosis What are causes of tricuspid stenosis? Causes of tricuspid stenosis can be divided into congenital and acquired causes. Congenital causes include tricuspid atresia or stenosis. Acquired causes include rheumatic heart disease, carcinoid syndrome, endocarditis, prior radiation, or fibrosis from endomyocardial procedures or placement of electrical leads. Rheumatic heart disease is the most common cause of tricuspid stenosis and is usually associated with mitral valvulopathy. What are the symptoms and physical exam findings of tricuspid stenosis? Findings revolve around right sided congestion or heart failure symptoms such as peripheral edema, abdominal distension with ascites, hepatomegaly, and jugular venous distension. When examining the jugular vein, you may see prominent a-waves and an almost absent or slow y descent reflective of delayed emptying of the right atrium (in the absence of tricuspid regurgitation). The murmur of tricuspid stenosis includes an opening snap and low diastolic murmur at the left lower sternal border with inspiratory accentuation. Patients may also report fatigue due to decreased cardiac output from obstruction.

How long should you anticoagulant for a PE? When can you safely stop anticoagulation for thrombogenic patients who need an urgent biopsy? Should an IVC filter be placed to prefer further embolization of a DVT? What percentage of patients with cancer associated blood clots will have progression while on anticoagulation?Show Notes, Transcript, and References: https://www.coreimpodcast.com/2022/02/23/24433/Get CME-MOC credit with ACP: https://www.acponline.org/cme-moc/cme/internal-medicine-podcasts/core-im Time Stamps:02:40 Deep Dive #1 Anticoagulation08:50 Deep Dive #2 DOACs14:08 Deep Dive #3 IVC Filter17:49 Deep Dive #4 Biopsy25:00 RecapTags: Core IM, IM Core, Anticoagulation, Bleeding, DOACs, IVC, reflections, clots